Metropolitan Digital

Google


.

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

  • Written by Ana Santos Rutschman, Professor of Law, Villanova University
FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccinesFederal health officials have raised safety concerns about mRNA vaccines, although they have provided no credible data on health risks.NurPhoto via Getty Images

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm...

Read more: FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of...